Optorhythm Israeli Company

OptoRhythm is developing a novel light-based method for controlling heart rhythms. Built on over 20 years of research by Prof. Lior Gepstein, a leader in cardiac electrophysiology and optogenetics, OptoRhythm’s approach aims to improve treatment for Atrial Fibrillation (AF). The technology integrates optogenetic gene therapy with an implantable micro-LED array to create the first Optic Defibrillator, designed to stop chaotic atrial contractions through targeted light pulses, offering an alternative to traditional electric shocks. This real-time, repeatable, and non-destructive approach addresses limitations in existing AF treatments, aiming for sustained rhythm control and improved patient outcomes.